We report a patient with rheumatoid arthritis who had a chronic leg ulcer with long-standing resistance to therapy. Topical basic fibroblast growth factor (bFGF) at a dose of 30 μg/day for 3 months was clinically effective in reducing the ulcer area by promoting angiogenesis, re-epithelization, granulation and scar formation. bFGF may be an effective treatment for therapy-resistant leg ulcers.
RyanTJBurnandK: Diseases of veins and arteries — leg ulcers. In: Textbook of Dermatology, 5th edn (ChampionRHBurtonJLEblingFJH, eds). Oxford: Blackwell Science, 1992; pp1963–2013.
2.
GospodarowiczD: Localization of a fibroblast growth factor and its effect alone and with hydrocortisone on 3T3 cell growth. Nature1974; 249: 123–127.
3.
IshibashiYSoedaSOhuraTNishikawaTNiimuraMNakajimaH: Clinical effects of KCB-1, a solution of recombinant human basic fibroblast growth factor, on skin ulcers: a phase 3 study comparing sugar and povidone-iodine ointment (in Japanese; English abstract). Rinsho Iyaku1996; 12: 2159–2187.
4.
Roberts-ThomsonPJWernickRMZiffM: Quantitation of rheumatoid factor by laser nephelometry. Rheumatol Int1982; 2: 17–20.
5.
SingerAJClarkRAF: Cutaneous wound healing. N Engl J Med1999; 341: 738–746.
6.
O'KeefeEJChiuMLPayneREJr: Stimulation of growth of keratinocytes by basic fibroblast growth factor. J Invest Dermatol1988; 90: 767–769.
7.
MontesanoRVassalliJDBairdAGuilleminROrciL: Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci U S A1986; 83: 7297–7301.
8.
KlingbeilCKCesarLBFiddlesJC: Basic fibroblast growth factor accelerates tissue repair in models of impaired wound healing. In: Clinical and Experimental Approaches to Dermal and Epidermal Repair: Normal and Chronic Wounds (BarbulACadwelMEagelsteinW, eds). New York, NY: Alan R Liss, 1991; pp443–458.
